Business Wire

Momcozy Survey Finds Moms Face Biggest Challenges of Time and Breast Pump Management, When Referring to Breastfeeding and Pumping Demands

23.2.2023 09:07:00 EET | Business Wire | Press release

Share

In a recent survey, Momcozy, the best-selling wearable breast pump brand in North America found that moms struggle with breastfeeding and breast pumping mostly due to a lack of time, space, and the right breast pump. In addition, wearable breast pumps that allow moms to pump hands-free anywhere to balance life enjoyment and nursing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230222005522/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Momcozy Breastfeeding and Pumping Experience Survey results (Graphic: Business Wire)

The survey was conducted from July 25th, 2022- September 13th, 2022, via Momcozy’s social media accounts and newsletter targeting North American moms, and garnered nearly 1000 responses, which found:

  • Moms face many hurdles to successful breastfeeding, including breast health issues, latching problems, and isolation sense. The most common difficulty however was managing the time to pump around busy schedules, along with the difficulties of breast pump management.
  • Generally, moms with wireless, wearable pumps reported more positive pumping experiences compared with their traditional breast pump counterparts.
  • Most respondents pump at home, at work, or in transit, indicating moms spend most of their time between taking care of their child, and earning income.
  • In terms of the ‘craziest’ place moms ever breast pumped, the most mentioned locations included at meetings, the grocery store, parties, and restaurants. Other locations mentioned such as festivals, amusement parks and sports games indicate that for some moms, wearable breast pumps allow them greater flexibility and freedom to do things they like.

These findings suggest that every minute of breastfeeding and expressing moms counts. While expressing goals can still be difficult, wearable breast pumps allow moms to express comfortably anytime, anywhere with confidence and freedom. In short, mothers have little time to choose when and where to express for themselves. But with a hands-free, wearable breast pump, moms can feel more secure pumping anywhere without missing out on the fun of their lives.

The Momcozy S12 Pro Wearable Breast Pump was developed with the full understanding of mothers' feeding needs. It can be seamlessly integrated into the busy schedule of mothers, providing an efficient breastfeeding experience and long battery life support to meet the needs of breastfeeding in various scenarios.“Always put moms on top” is what Momcozy has been fulfilling. Through cozy designs born from love and continuous innovation, Momcozy brings a much simpler, more relaxed, and more comfortable experience for moms globally through their pregnancy and early motherhood.

About Momcozy

Momcozy, the renowned maternity and baby brand endorsed by over 2 million moms, is the best companion for moms globally through their pregnancy and early motherhood. Centering around wearable breast pumps, Momcozy offers a wide range of products covering nursing, clothing and textile, FMCG, security, and more to accompany moms through their pregnancy and early motherhood in a more comfy and convenient way, making it the choice of Gen Z and millennial moms.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marketing Dept.
Ella Zheng
1-855-322-1777(Mon.-Fri. 8:30am-12:00pm;1:00pm-5:30pm PST)
ella.zheng@momcozy.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye